KLAS on Thursday printed a report that discovered healthcare suppliers are skeptical concerning the function digital well being data will play inside precision drugs initiatives.
WHY IT MATTERSThe concept that EHRs is not going to be the platform of selection for precision drugs shouldn’t be new.
Beth Israel Deaconess Medical Heart CIO Dr. John Halamka mentioned as a lot again in October of final 12 months on the HIMSS Huge Information and Healthcare Analytics Discussion board in Boston.
“Do I actually consider that the following precision drugs breakthrough is coming inside an EHR? No,” Halamka mentioned on the time. “It would come from third-parties … twenty-six-year-olds working of their storage to hyperlink improvements to EHRs utilizing FHIR APIs.”
The KLAS analysis, in truth, discovered that solely eight p.c of respondents see EHR merchandise taking a management function.
Forty-four p.c mentioned they assume EHRs will play a peripheral or supportive function, whereas 20 p.c mentioned EHRs shall be a central however non-leadership function and 28 p.c answered that the software program can have restricted or no function in precision drugs packages.
ON THE RECORDFrom the KLAS report: “Many respondents weren’t shy in expressing their emotions about EMR distributors’ roles, stating that the EMR in its present state is a hindrance to the development of the sphere and going as far as to name their vendor ‘a serious situation,’ ‘not succesful,’ or ‘not viable’ and state that precision drugs is ‘too advanced’ for EMR distributors to deal with.”
THE BIGGER PICTUREA precision drugs expertise market is coming collectively even when the EHR distributors will not be poised to dominate the realm. And hospitals all around the globe are embarking on precision drugs work.
Main well being methods resembling Geisinger, as an example, are taking steps to make precision drugs a regular of care quickly, whereas smaller and rural suppliers resembling Gibbs Most cancers and Analysis Institute in South Carolina are additionally making it work for them.
Likewise, the enterprise case for precision drugs is getting stronger as nicely. KLAS discovered that 59 p.c of respondents mentioned a enterprise case exists, whereas 25 p.c answered that it does however solely “considerably,” 12 p.c indicated that they don’t have a enterprise right now however count on one quickly and the remaining four p.c are not sure.
Twitter: @SullyHITEmail the author: firstname.lastname@example.org